These authors contributed equally.
Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk
Article first published online: 28 MAR 2012
© 2012 The Authors, Addiction Biology © 2012 Society for the Study of Addiction
Volume 19, Issue 2, pages 237–239, March 2014
How to Cite
Koenig, X., Kovar, M., Boehm, S., Sandtner, W. and Hilber, K. (2014), Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addiction Biology, 19: 237–239. doi: 10.1111/j.1369-1600.2012.00447.x
- Issue published online: 20 FEB 2014
- Article first published online: 28 MAR 2012
- Anti-addiction drug;
- cardiac arrhythmias;
- hERG potassium channels;
- indole alkaloid;
- QT interval prolongation
Ibogaine, an alkaloid derived from the African shrub Tabernanthe iboga, has shown promising anti-addictive properties in animals. Anecdotal evidence suggests that ibogaine is also anti-addictive in humans. Thus, it alleviates drug craving and impedes relapse of drug use. Although not licensed as therapeutic drug, and despite evidence that ibogaine may disturb the rhythm of the heart, this alkaloid is currently used as an anti-addiction drug in alternative medicine. Here, we report that therapeutic concentrations of ibogaine reduce currents through human ether-a-go-go-related gene potassium channels. Thereby, we provide a mechanism by which ibogaine may generate life-threatening cardiac arrhythmias.